Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRP-AM1977X vs levofloxacin in community-acquired pneumonia
jRCT2080222860Phase 3Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lascufloxacin in community-acquired pneumonia (CAP) (2 arms), sponsored by Kyorin Pharmaceutical. Primary endpoint: Clinical cure rate at test-of-cure. Started May 2015; status: completed.
02
Drugs
lascufloxacin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on jRCT2080222860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222860.